本帖最后由 老马 于 2012-1-13 21:20 编辑
Z5 _4 k& w4 _- g) K9 P: A# I/ e. H4 G @# O: o* O4 k
爱必妥和阿瓦斯丁的比较3 a( Q5 V) o2 s, I; X; r
4 `- Q- V# f7 N( e5 V9 \
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* g6 n0 C ?2 A/ S# C8 r
z) q: s4 s% f1 Y. h2 g7 j
* z2 I5 r( H! ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# n3 S# Z6 X9 T7 H' f& h# y
==================================================. P" r# y. x' D' p! c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% S, ^6 w& f. {/ x9 _, j( q9 WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., S/ h! z3 q* U% J
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 I( D0 o9 U2 h, s0 {2 c- x
|